more thorough etiological evaluation. External validation of SAFE in a multicenter study, with a larger number of patients, is warranted.
JAMA. 2022 Jun 28;327(24):2456. doi: 10.1001/jama.2022.7430. PMID: 35763000
BMC Neurol. 2022 Jun 9;22(1):215. doi: 10.1186/s12883-022-02740-z.PMID: 35681147
Neurobiol Dis. 2022 Jun 1;167:105671. doi: 10.1016/j.nbd.2022.105671. Epub 2022 Feb 26.PMID: 35231560
Interact J Med Res. 2022 Jun 9;11(1):e35698. doi: 10.2196/35698. PMID: 35485280
Thromb Haemost. 2022 Jun 19. doi: 10.1055/s-0042-1749328. Online ahead of print.PMID: 35717949
Antioxidants (Basel). 2022 Jun 16;11(6):1186. doi: 10.3390/antiox11061186. PMID: 35740081
Abstract: Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal
death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these resul
Funding: This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER) through grants PI18/00255, RD16/0019/0006,and RD21/0006/0019 to J.M. and A.A., and RD16/0019/0008 and RD21/0 006/0014 to J.B.S.; the MINECO grant SAF2015-65586-R to J.M.-C.; and the Comunidad de Madrid Neurocentro project B2017/BMD-3760 to D.G.-N.
BMC Ophthalmol. 2022 Jun 7;22(1):253. doi: 10.1186/s12886-022-02466-z. PMID: 35672688
Mol Ther Nucleic Acids. 2022 Mar 9;28:124-135. doi: 10.1016/j.omtn.2022.03.005. eCollection 2022 Jun 14. PMID: 35402075